Comparative Pharmacology
Head-to-head clinical analysis: DESMOPRESSIN ACETATE NEEDS NO REFRIGERATION versus NOCTIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMOPRESSIN ACETATE NEEDS NO REFRIGERATION versus NOCTIVA.
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) vs NOCTIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption, reducing urine output. Also transiently increases factor VIII and von Willebrand factor via V2 receptor activation on endothelium.
Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine volume.
Central diabetes insipidus: 0.1-0.4 mL (10-40 mcg) intranasally once or twice daily. Nocturnal enuresis: 20-40 mcg intranasally at bedtime. IV dosing for central diabetes insipidus: 2-4 mcg once daily subcutaneously or intravenously.
Desmopressin acetate: 1-2 sprays (10-20 mcg) intranasally once daily at bedtime; or 0.1-0.2 mg orally once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2.8-3.6 hours (range 1.5-5 hours). Prolonged in renal impairment (up to 8-10 hours) and in infants.
Terminal elimination half-life is 2-4 hours (mean 3.2 hours) in adults with normal renal function; prolonged to 6-9 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: >90% unchanged drug excreted in urine via glomerular filtration and tubular secretion. Fecal: negligible (<1%).
Renal excretion of unchanged drug accounts for approximately 70% of the dose; fecal elimination constitutes about 20%, with the remainder as metabolites.
Category A/B
Category C
Vasopressin Analog
Vasopressin Analog